{"id":121177,"date":"2026-03-10T17:29:48","date_gmt":"2026-03-11T00:29:48","guid":{"rendered":"https:\/\/ixcellsbiotech.com\/?p=121177"},"modified":"2026-03-13T06:41:08","modified_gmt":"2026-03-13T13:41:08","slug":"ixcells-large-scale-patient-derived-ipsc-lines","status":"publish","type":"post","link":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/","title":{"rendered":"iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"High\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab<\/b>\n<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

iXCells Biotechnologies USA, Inc. (\u201ciXCells\u201d), a leading provider of human cell-based solutions and custom iPSC services, today announced the delivery of over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The collaboration leverages iXCells\u2019 iPSCore platform<\/a>, which enables the large-scale generation of well-characterized patient-derived iPSC lines, to support the discovery and development of novel therapeutics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The platform supports drug discovery by enabling the creation, characterization and delivery of validated iPSC lines derived from diverse patient cohorts. iPSCore is delivering nearly 200 lines per month, with a reprogramming success rate exceeding 98%, and built-in cell banking at each stage to ensure continuity and mitigate risk. This scale allows researchers to study large patient cohorts, capturing population-level genetic diversity and minimizing background variance, which is critical for understanding complex diseases such as neurodegenerative disorders, oncology, cardiac disorders, or toxicology screening.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

iPSCore platform delivered over 500 characterized iPSC lines during first year of collaboration<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

To date, iXCells has delivered more than 500 characterized patient-derived iPSC lines under the collaboration, with more than 700 additional lines in development, demonstrating the scalability and efficiency of the iPSCore platform. The collaboration demonstrates iXCells\u2019 ability to deliver iPSC reprogramming at industrial scale, enabling high-throughput production of large volumes of patient-derived lines<\/a> while maintaining quality, reproducibility, and consistency. Further projects as part of the collaboration will expand the scale of the platform, including for differentiated cell types and disease-relevant models.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

The generation of validated iPSC lines using iPSCore is particularly meaningful in complex therapeutic areas where understanding patient diversity and disease biology is crucial. By enabling scalable access to high-quality, cohort-based iPSC models, iXCells is supporting researchers to generate comprehensive, population-relevant data sets, accelerating target identification and optimizing therapeutic strategies<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

Scaling Patient-Derived iPSC Models for Better Drug Discovery<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Steve Smith, CEO at iXCells Biotechnologies, said:<\/strong> “Reliable, large-scale access to patient-relevant cell models is revolutionizing our approach to disease research. By reaching this milestone in our collaboration, we are demonstrating that the right expertise and infrastructure can empower discovery teams to leverage diverse data from the very start, enabling delivering iPSC models at scale and dramatically improving the likelihood of successful drug development. Ongoing expansion of our iPSCore platform capabilities will enable large-scale access to high quality patient-derived human cell models to drive breakthroughs in drug discovery.\u201d<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Alex Gulotta, Board of Directors, iXCells Biotechnologies commented:<\/strong> ” iXCells\u2019 commitment to industrialization has fundamentally shifted the paradigm in drug discovery. Embedding patient-derived human cell models as foundational infrastructure throughout the drug development process enables hypothesis testing that truly reflects patient biology. What iXCells has built in iPSCore, and demonstrated through this collaboration, is exactly the kind of validated, scalable, revenue-generating platform that the industry needs and acquirers are looking for. This supports smarter, earlier decision-making, reducing costly late-stage failures and mitigating risk for stakeholders and partners.\u201d <\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t

About iXCells Biotechnologies<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

iXCells Biotechnologies (\u201ciXCells\u201d) is a leading San Diego, California-based cell technology company focused on generating a wide variety of predictive human disease models. In addition, iXCells is pursuing custom and patient-specific services leveraging its expertise in the preparation, handling, engineering and differentiation of induced pluripotent stem cells (iPSCs) and in the isolation of primary cells along with associated services for descriptive and functional cell characterization, compound screening and toxicology testing.<\/p>

The company\u2019s mission is to supply a diverse range of human disease models, derived from ethically sourced patient and healthy donor tissues, to support academic, pharmaceutical, and clinical researchers globally. By providing predictive human cell models, we aim to deepen the understanding of the molecular mechanisms underlying disease onset and progression as much as slow-down or reversion of disease, and accelerate the discovery and development of new medicines and innovative therapies to further advance precision medicine.<\/p>

Media Contacts<\/strong><\/p>

Christy Holt
VP, Marketing and Sales
christy.holt@ixcellsbiotech.com
iXCellsBiotech.com<\/a><\/p>

To request more information visit
iXCells on Linkedin,<\/a>
and iXCells on YouTube.<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
COMPANY NEWS<\/h6>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\n\t\t\t\t\t\t
\n\t\t\t\t\n\t\t\t\t<\/i>\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t\n\t\t\t\t\t\t
\n\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\t\n\t\t\t\t\t\t\tiXCells Reaches iPSC Line Delivery Milestone\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t

\n\t\t\t\t\t\tiXCells Biotechnologies announces delivery of over 500 characterized patient-derived iPSC lines through its iPSCore platform, enabling large-scale human disease modeling for drug discovery.\t\t\t\t\t<\/p>\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tContact A Scientist<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

iXCells Biotechnologies develops a diverse range of off-the-shelf and custom iPSC-derived cell models\u2014sourced from both healthy and patient donors\u2014with the goal of enabling \u201cclinical-trials-in-a-plate.\u201d<\/p>\n","protected":false},"author":234903478,"featured_media":121240,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"elementor_header_footer","format":"standard","meta":{"_acf_changed":false,"content-type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":true},"categories":[1889],"tags":[],"news_type":[2168],"news_areas":[],"class_list":["post-121177","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","news_type-company-news"],"acf":[],"yoast_head":"\niXCells Biotechnologies Reaches iPSC Line Delivery Milestone<\/title>\n<meta name=\"description\" content=\"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iXCells Biotechnologies Reaches iPSC Line Delivery Milestone\" \/>\n<meta property=\"og:description\" content=\"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/\" \/>\n<meta property=\"og:site_name\" content=\"iXCells\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T00:29:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-13T13:41:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"kfaulkner9a16998ec4\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@iXCells\" \/>\n<meta name=\"twitter:site\" content=\"@iXCells\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"kfaulkner9a16998ec4\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/\"},\"author\":{\"name\":\"kfaulkner9a16998ec4\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/person\\\/2a6cf137175bc92f940b947525db5651\"},\"headline\":\"iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab\",\"datePublished\":\"2026-03-11T00:29:48+00:00\",\"dateModified\":\"2026-03-13T13:41:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/\"},\"wordCount\":701,\"publisher\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/High-Throughput-Featured-Image-V02d.jpg\",\"articleSection\":[\"Company News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/\",\"name\":\"iXCells Biotechnologies Reaches iPSC Line Delivery Milestone\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/High-Throughput-Featured-Image-V02d.jpg\",\"datePublished\":\"2026-03-11T00:29:48+00:00\",\"dateModified\":\"2026-03-13T13:41:08+00:00\",\"description\":\"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/High-Throughput-Featured-Image-V02d.jpg\",\"contentUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/High-Throughput-Featured-Image-V02d.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/ixcells-large-scale-patient-derived-ipsc-lines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#website\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\",\"name\":\"iXCells Biotechnologies\",\"description\":\"Human Relevant Cell Model Expert | iPSC | Primary Cells\",\"publisher\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ixcellsbiotech.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#organization\",\"name\":\"iXCells Biotechnologies USA, Inc.\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo.png\",\"contentUrl\":\"https:\\\/\\\/ixcellsbiotech.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Logo.png\",\"width\":256,\"height\":64,\"caption\":\"iXCells Biotechnologies USA, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/iXCells\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ixcells-biotechnologies\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ixcellsbiotech.com\\\/#\\\/schema\\\/person\\\/2a6cf137175bc92f940b947525db5651\",\"name\":\"kfaulkner9a16998ec4\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g\",\"caption\":\"kfaulkner9a16998ec4\"},\"url\":\"https:\\\/\\\/ixcellsbiotech.com\\\/author\\\/kfaulkner9a16998ec4\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iXCells Biotechnologies Reaches iPSC Line Delivery Milestone","description":"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/","og_locale":"en_US","og_type":"article","og_title":"iXCells Biotechnologies Reaches iPSC Line Delivery Milestone","og_description":"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.","og_url":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/","og_site_name":"iXCells","article_published_time":"2026-03-11T00:29:48+00:00","article_modified_time":"2026-03-13T13:41:08+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","type":"image\/jpeg"}],"author":"kfaulkner9a16998ec4","twitter_card":"summary_large_image","twitter_creator":"@iXCells","twitter_site":"@iXCells","twitter_misc":{"Written by":"kfaulkner9a16998ec4","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#article","isPartOf":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/"},"author":{"name":"kfaulkner9a16998ec4","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/person\/2a6cf137175bc92f940b947525db5651"},"headline":"iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab","datePublished":"2026-03-11T00:29:48+00:00","dateModified":"2026-03-13T13:41:08+00:00","mainEntityOfPage":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/"},"wordCount":701,"publisher":{"@id":"https:\/\/ixcellsbiotech.com\/#organization"},"image":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#primaryimage"},"thumbnailUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","articleSection":["Company News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/","url":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/","name":"iXCells Biotechnologies Reaches iPSC Line Delivery Milestone","isPartOf":{"@id":"https:\/\/ixcellsbiotech.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#primaryimage"},"image":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#primaryimage"},"thumbnailUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","datePublished":"2026-03-11T00:29:48+00:00","dateModified":"2026-03-13T13:41:08+00:00","description":"Discover iPSC advancements from iXCells Biotechnologies, including the delivery of over 500 characterized stem cell lines.","breadcrumb":{"@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#primaryimage","url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","contentUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/ixcellsbiotech.com\/ixcells-large-scale-patient-derived-ipsc-lines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ixcellsbiotech.com\/"},{"@type":"ListItem","position":2,"name":"iXCells Offers High-Throughput iPSC Production Built as an Extension of Your Lab"}]},{"@type":"WebSite","@id":"https:\/\/ixcellsbiotech.com\/#website","url":"https:\/\/ixcellsbiotech.com\/","name":"iXCells Biotechnologies","description":"Human Relevant Cell Model Expert | iPSC | Primary Cells","publisher":{"@id":"https:\/\/ixcellsbiotech.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ixcellsbiotech.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ixcellsbiotech.com\/#organization","name":"iXCells Biotechnologies USA, Inc.","url":"https:\/\/ixcellsbiotech.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/logo\/image\/","url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2023\/06\/Logo.png","contentUrl":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2023\/06\/Logo.png","width":256,"height":64,"caption":"iXCells Biotechnologies USA, Inc."},"image":{"@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/iXCells","https:\/\/www.linkedin.com\/company\/ixcells-biotechnologies"]},{"@type":"Person","@id":"https:\/\/ixcellsbiotech.com\/#\/schema\/person\/2a6cf137175bc92f940b947525db5651","name":"kfaulkner9a16998ec4","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89a7d563dce165323e2b05f8231899e8226ded71ae78e1309cc6d4e045087a52?s=96&d=identicon&r=g","caption":"kfaulkner9a16998ec4"},"url":"https:\/\/ixcellsbiotech.com\/author\/kfaulkner9a16998ec4\/"}]}},"jetpack_publicize_connections":[],"jetpack_shortlink":"https:\/\/wp.me\/peN4gs-vwt","jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/ixcellsbiotech.com\/wp-content\/uploads\/2026\/03\/High-Throughput-Featured-Image-V02d.jpg","_links":{"self":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/121177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/users\/234903478"}],"replies":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/comments?post=121177"}],"version-history":[{"count":15,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/121177\/revisions"}],"predecessor-version":[{"id":121353,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/posts\/121177\/revisions\/121353"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/media\/121240"}],"wp:attachment":[{"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/media?parent=121177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/categories?post=121177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/tags?post=121177"},{"taxonomy":"news_type","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/news_type?post=121177"},{"taxonomy":"news_areas","embeddable":true,"href":"https:\/\/ixcellsbiotech.com\/wp-json\/wp\/v2\/news_areas?post=121177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}